Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
PAD. ICORG 05-01, V11
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 53
- Registration Number
- NCT00814541
- Locations
- 🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇮🇪Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Janssen-Cilag G.m.b.H
- Target Recruit Count
- 96
- Registration Number
- NCT00813150
Steroid-induced Reduction of Surgical Stress Study
- Conditions
- Coronary Artery Bypass Graft SurgeryCoronary Artery Stenosis
- Interventions
- Drug: PlaceboDrug: Dexamethasone
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Registration Number
- NCT00807521
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Combined Therapy in Age-Related Macular Degeneration (ARMD)
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Drug: bevacizumabProcedure: Low fluorescence Photodynamic therapyProcedure: core pars plana vitrectomyDrug: dexamethasoneDrug: triamcincolone
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00805649
- Locations
- 🇩🇪
Abteilung für Netzhaut und Glaskörperchirurgie, Frankfurt/Main, Hessen, Germany
Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 44
- Registration Number
- NCT00802009
- Locations
- 🇨🇦
Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine
- Conditions
- Anesthesia, LocalShoulder Surgery
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 218
- Registration Number
- NCT00801138
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 56
- Registration Number
- NCT00799227
Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia
- Conditions
- Anaesthetics Gases, XenonAnaesthetics Volatile, SevofluraneDepth of AnaesthesiaPostoperative NauseaPostoperative Vomiting
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- RWTH Aachen University
- Target Recruit Count
- 220
- Registration Number
- NCT00793663
- Locations
- 🇩🇪
RWTH Aachen University; Department of Anesthesiology, Aachen, Germany
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Adult L1 Acute Lymphoblastic LeukemiaAdult L2 Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: DasatinibDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: MethotrexateDrug: MethylprednisoloneProcedure: Peripheral Blood Stem Cell TransplantationDrug: PrednisoneDrug: SirolimusDrug: TacrolimusRadiation: Total-Body IrradiationDrug: Vincristine Sulfate
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT00792948
- Locations
- 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸Southwest Medical Center, Liberal, Kansas, United States
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmNeurotoxicity
- Interventions
- Drug: bortezomibDrug: dexamethasoneDrug: melphalanDrug: thalidomideGenetic: cytogenetic analysisGenetic: fluorescence in situ hybridizationOther: laboratory biomarker analysisOther: questionnaire administrationProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT00792142
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.